CDKN2A and renal cell adenocarcinoma: CDKN2A is considered a key target for 9p deletions in multiple tumors, particularly RCC, due to its frequent inactivation through homozygous deletions or hypermethylation in the promoter region (Vidaurreta et al., 2008; Schraml et al., 2001).